In today’s digital age, misinformation spreads faster than ever, often driven by sensational headlines and influencer content ...

Yet this simple difference translated into a median progression-free survival (PFS) of 11.3 months versus 5.7 months for ...

Novo Nordisk’s Alhemo (concizumab-mtci) has been approved by the US Food and Drug Administration (FDA) to prevent or reduce ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...